Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and key secondary endpoints in a 12-week, Phase 3 study investigating its efficacy in the treatment of moderate to severe atopic dermatitis (AD) in patients aged 12 and older.
The findings revealed that 43.8% and 23.7% of patients achieved an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin with 200mg and 100mg of abrocitinib respectively compared to placebo – one of the trial’s co-primary endpoints.
